WEGOVY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Wegovy, and what generic alternatives are available?
Wegovy is a drug marketed by Novo and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-seven patent family members in thirty-two countries.
The generic ingredient in WEGOVY is semaglutide. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.
DrugPatentWatch® Generic Entry Outlook for Wegovy
Wegovy was eligible for patent challenges on December 5, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 5, 2031. This may change due to patent challenges or generic licensing.
There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WEGOVY?
- What are the global sales for WEGOVY?
- What is Average Wholesale Price for WEGOVY?
Summary for WEGOVY
| International Patents: | 147 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 16 |
| Clinical Trials: | 12 |
| Patent Applications: | 702 |
| Drug Prices: | Drug price information for WEGOVY |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for WEGOVY |
| What excipients (inactive ingredients) are in WEGOVY? | WEGOVY excipients list |
| DailyMed Link: | WEGOVY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for WEGOVY
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for WEGOVY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme LLC | Phase 2 |
| Psychiatric Centre Rigshospitalet | Phase 2 |
| Neurobiology Research Unit | Phase 2 |
Pharmacology for WEGOVY
| Drug Class | GLP-1 Receptor Agonist |
| Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
Paragraph IV (Patent) Challenges for WEGOVY
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| WEGOVY | Injection | semaglutide | 0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL | 215256 | 1 | 2022-10-20 |
US Patents and Regulatory Information for WEGOVY
WEGOVY is protected by seven US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of WEGOVY is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting WEGOVY
GLP-1 compositions and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR WEIGHT MANAGEMENT
GLP-1 compositions and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR WEIGHT MANAGEMENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR WEIGHT MANAGEMENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR WEIGHT MANAGEMENT
Acylated GLP-1 compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Acylated GLP-1 compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Use of long-acting GLP-1 peptides
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
FDA Regulatory Exclusivity protecting WEGOVY
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
IN COMBINATION WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, OR NON-FATAL STROKE) IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE AND EITHER OBESITY OR OVERWEIGHT
Exclusivity Expiration: ⤷ Sign Up
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
USE OF SEMAGLUTIDE 1.7 MG SUBCUTANEOUS WEEKLY AS AN ADDITIONAL MAINTENANCE DOSE
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-005 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-004 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-005 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-004 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-004 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for WEGOVY
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk A/S | Wegovy | semaglutide | EMEA/H/C/005422 Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to |
Authorised | no | no | no | 2022-01-06 | |
| Novo Nordisk A/S | Ozempic | semaglutide | EMEA/H/C/004174 Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. |
Authorised | no | no | no | 2018-02-08 | |
| Novo Nordisk A/S | Rybelsus | semaglutide | EMEA/H/C/004953 Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. |
Authorised | no | no | no | 2020-04-03 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for WEGOVY
When does loss-of-exclusivity occur for WEGOVY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06224536
Patent: Acylated GLP-1 compounds
Estimated Expiration: ⤷ Sign Up
Austria
Patent: 76446
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0607762
Patent: anÁlogo de glp-1, mÉtodo para aumentar o tempo de aÇço em um paciente de um anÁlogo de glp-1, composiÇço farmacÊutica, e, uso de um composto
Estimated Expiration: ⤷ Sign Up
Patent: 2019002626
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 01784
Patent: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1133082
Patent: Acylated GLP-1 compounds
Estimated Expiration: ⤷ Sign Up
Patent: 4017062
Patent: Acylated GLP-1 compounds
Estimated Expiration: ⤷ Sign Up
Patent: 4402989
Patent: ACYLATED GLP-1 COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 63839
Estimated Expiration: ⤷ Sign Up
Patent: 22546
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 63839
Patent: COMPOSES DE GLP-1 ACYLES (ACYLATED GLP-1 COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 22546
Patent: Composés GLP-1 acylés (Acylated GLP-1 compounds)
Estimated Expiration: ⤷ Sign Up
Germany
Patent: 2006015928
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 28194
Estimated Expiration: ⤷ Sign Up
Patent: 800019
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 4051
Patent: תרכובות glp-1 שעברו אצילציה, תכשירי רוקחות המכילים אותן ושימוש בהן להכנת תרופות (Acylated glp-1 compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 85037
Estimated Expiration: ⤷ Sign Up
Patent: 09463
Estimated Expiration: ⤷ Sign Up
Patent: 08533105
Estimated Expiration: ⤷ Sign Up
Patent: 10116407
Patent: ACYLATED GLP-1 COMPOUND
Estimated Expiration: ⤷ Sign Up
Patent: 13063984
Patent: ACYLATED GLP-1 COMPOUND
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 07011220
Patent: COMPUESTOS DE PEPTIDO 1 TIPO GLUCAGON ACILADOS. (ACYLATED GLP-1 COMPOUNDS.)
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 0936
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 7946
Estimated Expiration: ⤷ Sign Up
Patent: 18023
Estimated Expiration: ⤷ Sign Up
Patent: 075342
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 63839
Estimated Expiration: ⤷ Sign Up
Patent: 22546
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 63839
Estimated Expiration: ⤷ Sign Up
Patent: 22546
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 34019
Patent: АЦИЛИРОВАННЫЕ GLP-1 СОЕДИНЕНИЯ (ACYLATED GLP-1 COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 07134156
Patent: АЦИЛИРОВАННЫЕ GLP-1 СОЕДИНЕНИЯ
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0707261
Patent: Acylated GLP-1 compounds
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1205272
Estimated Expiration: ⤷ Sign Up
Patent: 070120089
Patent: ACYLATED GLP-1 COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 50051
Estimated Expiration: ⤷ Sign Up
Patent: 57313
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 62392
Estimated Expiration: ⤷ Sign Up
Patent: 72629
Estimated Expiration: ⤷ Sign Up
Patent: 0700433
Patent: Acylated glp-1 compounds
Estimated Expiration: ⤷ Sign Up
Patent: 0942255
Patent: Acylated GLP-1 compounds
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering WEGOVY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2022132414 | 医学療法におけるセマグルチド | ⤷ Sign Up |
| Brazil | 112014032938 | uso de peptídeos de glp-1 de longa ação | ⤷ Sign Up |
| European Patent Office | 3474820 | COMPOSITIONS DE GLP-1 ET LEURS UTILISATIONS (GLP-1 COMPOSITIONS AND USES THEREOF) | ⤷ Sign Up |
| Spain | 2557313 | ⤷ Sign Up | |
| Chile | 2022002084 | Formulaciones farmacéuticas | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for WEGOVY
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1863839 | C01863839/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018 |
| 1863839 | 122018000075 | Germany | ⤷ Sign Up | PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208 |
| 1863839 | SPC/GB18/023 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: SEMAGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1251 (NI) 20180208; UK PLGB 04668/0331 20180208; UK PLGB 04668/0332 20180208; UK PLGB 04668/0333 20180208 |
| 1863839 | 18C1017 | France | ⤷ Sign Up | PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180212 |
| 1863839 | 22/2018 | Austria | ⤷ Sign Up | PRODUCT NAME: SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
